These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

560 related articles for article (PubMed ID: 25639776)

  • 1. Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials.
    Boquete-Castro A; Gómez-Moreno G; Calvo-Guirado JL; Aguilar-Salvatierra A; Delgado-Ruiz RA
    Clin Oral Implants Res; 2016 Mar; 27(3):367-75. PubMed ID: 25639776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence rate of osteonecrosis of jaw after cancer treated with bisphosphonates and denosumab: A systematic review and meta-analysis.
    Zhang C; Shen G; Li H; Xin Y; Shi M; Zheng Y; Wang M; Liu Z; Zhao Y; Zhao F; Ren D; Zhao J
    Spec Care Dentist; 2024; 44(2):530-541. PubMed ID: 37219080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials.
    Qi WX; Tang LN; He AN; Yao Y; Shen Z
    Int J Clin Oncol; 2014 Apr; 19(2):403-10. PubMed ID: 23605142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab.
    Loyson T; Van Cann T; Schöffski P; Clement PM; Bechter O; Spriet I; Coropciuc R; Politis C; Vandeweyer RO; Schoenaers J; Dumez H; Berteloot P; Neven P; Nackaerts K; Woei-A-Jin FJSH; Punie K; Wildiers H; Beuselinck B
    Acta Clin Belg; 2018 Apr; 73(2):100-109. PubMed ID: 28693379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of Osteonecrosis of the Jaw Under Denosumab Compared to Bisphosphonates in Patients With Osteoporosis.
    Everts-Graber J; Lehmann D; Burkard JP; Schaller B; Gahl B; Häuselmann H; Studer U; Ziswiler HR; Reichenbach S; Lehmann T
    J Bone Miner Res; 2022 Feb; 37(2):340-348. PubMed ID: 34787342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk comparison of osteonecrosis of the jaw in osteoporotic patients treated with bisphosphonates vs. denosumab: a multi-institutional retrospective cohort study in Taiwan.
    Liu FC; Luk KC; Chen YC
    Osteoporos Int; 2023 Oct; 34(10):1729-1737. PubMed ID: 37326685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteonecrosis of the jaw among patients with cancer treated with denosumab or zoledronic acid: Results of a regulator-mandated cohort postauthorization safety study in Denmark, Norway, and Sweden.
    Ehrenstein V; Heide-Jørgensen U; Schiødt M; Akre O; Herlofson BB; Hansen S; Larsson Wexell C; Nørholt SE; Tretli S; Kjellman A; Glennane A; Lowe KA; Sørensen HT
    Cancer; 2021 Nov; 127(21):4050-4058. PubMed ID: 34310704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiresorptive treatment-associated ONJ.
    Eleutherakis-Papaiakovou E; Bamias A
    Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 29063702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.
    Turner B; Drudge-Coates L; Ali S; Pati J; Nargund V; Ali E; Cheng L; Wells P
    Urol Nurs; 2016; 36(3):111-6, 154. PubMed ID: 27501591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-induced osteonecrosis of the jaw: the state of the art.
    Fassio A; Bertoldo F; Idolazzi L; Viapiana O; Rossini M; Gatti D
    Reumatismo; 2017 May; 69(1):9-15. PubMed ID: 28535616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ.
    Khan AA; Morrison A; Kendler DL; Rizzoli R; Hanley DA; Felsenberg D; McCauley LK; O'Ryan F; Reid IR; Ruggiero SL; Taguchi A; Tetradis S; Watts NB; Brandi ML; Peters E; Guise T; Eastell R; Cheung AM; Morin SN; Masri B; Cooper C; Morgan SL; Obermayer-Pietsch B; Langdahl BL; Dabagh RA; Davison KS; Sándor GK; Josse RG; Bhandari M; El Rabbany M; Pierroz DD; Sulimani R; Saunders DP; Brown JP; Compston J;
    J Clin Densitom; 2017; 20(1):8-24. PubMed ID: 27956123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences between bisphosphonate-related and denosumab-related osteonecrosis of the jaws: a systematic review.
    Querrer R; Ferrare N; Melo N; Stefani CM; Dos Reis PED; Mesquita CRM; Borges GA; Leite AF; Figueiredo PT
    Support Care Cancer; 2021 Jun; 29(6):2811-2820. PubMed ID: 33140246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An evidence-based review of risk-reductive strategies for osteonecrosis of the jaws among cancer patients.
    Kyrgidis A; Tzellos TG; Toulis K; Arora A; Kouvelas D; Triaridis S
    Curr Clin Pharmacol; 2013 May; 8(2):124-34. PubMed ID: 23092218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid onset of osteonecrosis of the jaw in patients switching from bisphosphonates to denosumab.
    Yarom N; Lazarovici TS; Whitefield S; Weissman T; Wasserzug O; Yahalom R
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2018 Jan; 125(1):27-30. PubMed ID: 29102242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteonecrosis of the jaw in patients transitioning from bisphosphonates to denosumab treatment for osteoporosis.
    Voss PJ; Steybe D; Poxleitner P; Schmelzeisen R; Munzenmayer C; Fuellgraf H; Stricker A; Semper-Hogg W
    Odontology; 2018 Oct; 106(4):469-480. PubMed ID: 29713913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Denosumab-related osteonecrosis of the jaw: a case report and management based on pharmacokinetics.
    You Tm; Lee KH; Lee SH; Park W
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2015 Nov; 120(5):548-53. PubMed ID: 26337218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What is the Risk of Developing Osteonecrosis Following Dental Extractions for Patients on Denosumab for Osteoporosis?
    Colella A; Yu E; Sambrook P; Hughes T; Goss A
    J Oral Maxillofac Surg; 2023 Feb; 81(2):232-237. PubMed ID: 36442534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Risk of Medication-Related Osteonecrosis of the Jaw in Children: Guidance for Antiresorptive Use in Pediatric Patients.
    Lasky S; Moshal T; Shakoori P; Roohani I; Jolibois M; Youn S; Urata MM; Hammoudeh JA
    J Oral Maxillofac Surg; 2024 Oct; 82(10):1285-1294. PubMed ID: 38950582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases.
    Saad F; Brown JE; Van Poznak C; Ibrahim T; Stemmer SM; Stopeck AT; Diel IJ; Takahashi S; Shore N; Henry DH; Barrios CH; Facon T; Senecal F; Fizazi K; Zhou L; Daniels A; Carrière P; Dansey R
    Ann Oncol; 2012 May; 23(5):1341-1347. PubMed ID: 21986094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteonecrosis of the jaw induced by receptor activator of nuclear factor-kappa B ligand (Denosumab) - Review.
    de Oliveira CC; Brizeno LA; de Sousa FB; Mota MR; Alves AP
    Med Oral Patol Oral Cir Bucal; 2016 Jul; 21(4):e431-9. PubMed ID: 26827069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.